News

“Our collaboration with Hansoh Pharma strengthens our ability to commercialize inebilizumab throughout the world,” commented Bing Yao, Ph.D., Viela’s Executive Chairman and Chief Executive Officer. “Their significant commercial,

CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.

Transgene confirms that the study’s primary endpoint (objective response rate – ORR) on a minimum of 35 evaluable patients will be reported in Q4 2019. The Phase 2

The settlement resolves the state’s claims against Teva. The settlement does not establish any wrongdoing on the part of the company; Teva has not contributed to the abuse

Lyrica could not show a statistically significant reduction in seizure frequency in comparison to placebo in the late-stage trial held in 219 patients aged between five and 65

Neuraxpharm has entered into an exclusive licensing agreement with the probiotics company Bened Biomedical, under which Neuraxpharm secured exclusive rights to market its first probiotic lactobacillus plantarum PS128

The FDA has approved Piqray kinase inhibitor in combination with fulvestrant to treat postmenopausal women, and men with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-),

“Today’s approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” said Acting FDA Commissioner Ned Sharpless, M.D.

KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were